Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions-Reference-Cited by-同舟云学术

Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions

Published:2009-04-01 Issue:4 Volume:14 Page:378-390
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Morabito Alessandro¹,Piccirillo Maria Carmela¹,Falasconi Fabiano¹,De Feo Gianfranco¹,Del Giudice Antonia¹,Bryce Jane¹,Di Maio Massimo¹,De Maio Ermelinda¹,Normanno Nicola²³,Perrone Francesco¹

Affiliation:

1. a Clinical Trials Unit, National Cancer Institute, Napoli, Italy

2. b Cellular Biology and Biotherapy, National Cancer Institute, Napoli, Italy

3. c Centro di Ricerche Oncologiche di Mercogliano (CROM), Mercogliano (AV), Italy

Abstract

Learning Objectives Evaluate the mechanism of action of vandetanib in the care of patients with thyroid cancer. Analyze the current status of clinical development and early clinical results observed with vandetanib. Determine appropriate dose and schedule of administration, safety, and identification of molecular biomarkers predictive of response. This article is available for continuing medical education credit at CME.TheOncologist.com.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2008-0261

Reference60 articles.

1. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors;Hennequin;J Med Chem,2002

2. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases;Carlomagno;Cancer Res,2002

3. The hallmarks of cancer;Hanahan;Cell,2000

4. Molecular and biological properties of vascular endothelial growth factor;Ferrara;J Mol Med,1999

5. The biology of VEGF and its receptors;Ferrara;Nat Med,2003

Cited by 174 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review;Future Oncology;2024-08-12

2. Evaluation of 1,10-phenanthroline-based hydroxamate derivative as dual histone deacetylases/ribonucleotide reductase inhibitor with antitumor activities;DARU Journal of Pharmaceutical Sciences;2024-04-29

3. DESIGNING, SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLINE DERIVATIVES TARGETING PANCREATIC CANCER CELLS;INDIAN DRUGS;2023-09-28

4. Innovative Approaches to Campus Sustainability: Developing an Electric Cycle App for College Students;2023 Second International Conference On Smart Technologies For Smart Nation (SmartTechCon);2023-08-18

5. Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present);Pharmaceuticals;2023-04-03